- Region
- Águilas
- Alhama de Murcia
- Jumilla
- Lorca
- Los Alcázares
- Mazarrón
- San Javier
-
ALL AREAS & TOWNS
- AREAS
- SOUTH WEST
- MAR MENOR
- MURCIA CITY & CENTRAL
- NORTH & NORTH WEST
- TOWNS
- Abanilla
- Abarán
- Aguilas
- Alamillo
- Alcantarilla
- Aledo
- Alhama de Murcia
- Archena
- Balsicas
- Blanca
- Bolnuevo
- Bullas
- Cañadas del Romero
- Cabo de Palos
- Calasparra
- Camping Bolnuevo
- Campo De Ricote
- Camposol
- Canada De La Lena
- Caravaca de la Cruz
- Cartagena
- Cehegin
- Ceuti
- Cieza
- Condado de Alhama
- Corvera
- Costa Cálida
- Cuevas De Almanzora
- Cuevas de Reyllo
- El Carmoli
- El Mojon
- El Molino (Puerto Lumbreras)
- El Pareton / Cantareros
- El Raso
- El Valle Golf Resort
- Fortuna
- Fuente Alamo
- Hacienda del Alamo Golf Resort
- Hacienda Riquelme Golf Resort
- Isla Plana
- Islas Menores & Mar de Cristal
- Jumilla
- La Azohia
- La Charca
- La Manga Club
- La Manga del Mar Menor
- La Pinilla
- La Puebla
- La Torre
- La Torre Golf Resort
- La Unión
- Las Palas
- Las Ramblas
- Las Ramblas Golf
- Las Torres de Cotillas
- Leiva
- Librilla
- Lo Pagan
- Lo Santiago
- Lorca
- Lorquí
- Los Alcázares
- Los Balcones
- Los Belones
- Los Canovas
- Los Nietos
- Los Perez (Tallante)
- Los Urrutias
- Los Ventorrillos
- Mar De Cristal
- Mar Menor
- Mar Menor Golf Resort
- Mazarrón
- Mazarrón Country Club
- Molina de Segura
- Moratalla
- Mula
- Murcia City
- Murcia Property
- Pareton
- Peraleja Golf Resort
- Perin
- Pilar de la Horadada
- Pinar de Campoverde
- Pinoso
- Playa Honda
- Playa Honda / Playa Paraíso
- Pliego
- Portmán
- Pozo Estrecho
- Puerto de Mazarrón
- Puerto Lumbreras
- Puntas De Calnegre
- Region of Murcia
- Ricote
- Roda Golf Resort
- Roldan
- Roldan and Lo Ferro
- San Javier
- San Pedro del Pinatar
- Santiago de la Ribera
- Sierra Espuña
- Sucina
- Tallante
- Terrazas de la Torre Golf Resort
- Torre Pacheco
- Totana
- What's On Weekly Bulletin
- Yecla
- EDITIONS: Spanish News Today Alicante Today Andalucia Today
ARCHIVED - Oxford vaccine trials suspended due to volunteer illness; no vaccine for Spain in December
The pharmaceutical company, with which the EU has signed an agreement for the acquisition of 300 million doses, reports that one of the participants has suffered a "potentially unexplained" disease
Just on Monday the Spanish Minister for Health, Salvador Illa had announced that Spain could potentially expect to have about three million doses of this vaccine available in December, of the 30 million that are already ordered.
But hopes placed on the vaccine being developed by the University of Oxford together with the British pharmaceutical company AstraZeneca have suffered a setback this Wednesday: one of the participants in the clinical trial has suffered a "potentially unexplained" disease that, according to the newspaper The New York Times, it is a myelitis that causes an inflammation of the spine.
Vicente Larraga, a researcher at the CSIC's molecular parasitology laboratory says that "it is not at all strange that this could happen" as the tests are carried out precisely to rule out possible side effects. For the moment, the tests have been interrupted and researchers are trying to find out if the origin of the reaction is due to the vaccine or for another reason.
As a consequence of this interruption in the tests, forecasts for when the vaccine will be available must be recalculated again.
Although this is a setback, Larraga says that "it is more important that the vaccines are safe than that they reach the market a month earlier."
AstraZeneca said in a statement that, “As part of the ongoing global randomized controlled trials of the Oxford coronavirus vaccine, our standard review process has paused vaccination to allow for review of safety data. This is a routine action that has to be done whenever there is a potentially unexplained illness in one of the trials, ensuring that we maintain their integrity ", added AstraZeneca, as reported by the US press.
The drugmaker has added that, in large trials, "diseases will appear by chance," but these conditions "must be independently reviewed to check (the data) carefully."
In this context, AstraZeneca has assured that it is working to "accelerate the review" of this "unique event" with the aim of "minimizing any potential impact on the trial timeline". It has also assured that it is "committed" to the "safety" of the study participants, while highlighting the "highest standards of conduct" in its trials.
This will naturally cause a delay in delivery of the first doses, making it more likely that the vaccine will not be available in Spain until next year.